Literature DB >> 30806972

Esaxerenone: First Global Approval.

Sean Duggan1.   

Abstract

Esaxerenone (MINNEBRO™)-a novel oral, non-steroidal, selective mineralocorticoid receptor blocker-is being developed by Daiichi Sankyo for the treatment of hypertension and diabetic nephropathies. In January 2019, based on positive results from a phase III trial conducted in Japan in patients with essential hypertension, esaxerenone received marketing approval in Japan for the treatment of hypertension. This article summarizes the milestones in the development of esaxerenone leading to this first global approval for the treatment of hypertension.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30806972     DOI： 10.1007/s40265-019-01073-5

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  7 in total

1.  Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects.

Authors:  Manabu Kato; Hidetoshi Furuie; Takako Shimizu; Atsuhiro Miyazaki; Fumiaki Kobayashi; Hitoshi Ishizuka
Journal:  Br J Clin Pharmacol       Date:  2018-06-07       Impact factor: 4.335

2.  Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.

Authors:  Kiyoshi Arai; Tsuyoshi Homma; Yuka Morikawa; Naoko Ubukata; Hiyoyuki Tsuruoka; Kazumasa Aoki; Hirokazu Ishikawa; Makoto Mizuno; Toshio Sada
Journal:  Eur J Pharmacol       Date:  2015-06-11       Impact factor: 4.432

Review 3.  Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension.

Authors:  Shigeru Shibata; Kenichi Ishizawa; Shunya Uchida
Journal:  Hypertens Res       Date:  2016-10-20       Impact factor: 3.872

4.  Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans.

Authors:  Makiko Yamada; Jeanne Mendell; Hideo Takakusa; Takako Shimizu; Osamu Ando
Journal:  Drug Metab Dispos       Date:  2018-12-12       Impact factor: 3.922

5.  CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats.

Authors:  Kiyoshi Arai; Hiroyuki Tsuruoka; Tsuyoshi Homma
Journal:  Eur J Pharmacol       Date:  2015-11-26       Impact factor: 4.432

Review 6.  Mineralocorticoid receptor blockade in the protection of target organ damage.

Authors:  Paolo Mulatero; Alberto Milan; Tracy Ann Williams; Franco Veglio
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2006-01

7.  CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats.

Authors:  Kiyoshi Arai; Yuka Morikawa; Naoko Ubukata; Hiroyuki Tsuruoka; Tsuyoshi Homma
Journal:  J Pharmacol Exp Ther       Date:  2016-07-06       Impact factor: 4.030
  7 in total
  20 in total

Review 1.  Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm.

Authors:  Michael R Lattanzio; Matthew R Weir
Journal:  Kidney360       Date:  2020-07-23

Review 2.  Hypertension and Type 2 Diabetes-The Novel Treatment Possibilities.

Authors:  Agnieszka Przezak; Weronika Bielka; Andrzej Pawlik
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

3.  A Case of a Pregnant Woman With Primary Aldosteronism and Superimposed Preeclampsia Treated With Esaxerenone.

Authors:  Kaoru Yamashita; Satoshi Morimoto; Yuko Inoue; Kiyotaka Hirata; Shihori Kimura; Yasufumi Seki; Kanako Bokuda; Daisuke Watanabe; Atsuhiro Ichihara
Journal:  J Endocr Soc       Date:  2022-05-29

Review 4.  Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms.

Authors:  Johann Bauersachs; Achim Lother
Journal:  Kidney Int Suppl (2011)       Date:  2022-03-18

5.  Latest hypertension research to inform clinical practice in Asia.

Authors:  Kazuomi Kario; Masaki Mogi; Satoshi Hoshide
Journal:  Hypertens Res       Date:  2022-04-05       Impact factor: 5.528

6.  Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects.

Authors:  Yoshiaki Kirigaya; Masanari Shiramoto; Tomoko Ishizuka; Hinako Uchimaru; Shin Irie; Manabu Kato; Takako Shimizu; Takafumi Nakatsu; Yasuhiro Nishikawa; Hitoshi Ishizuka
Journal:  BMC Pharmacol Toxicol       Date:  2020-07-29       Impact factor: 2.483

7.  Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.

Authors:  Kiyoshi Arai; Yuka Morikawa; Naoko Ubukata; Kotaro Sugimoto
Journal:  Hypertens Res       Date:  2020-07-02       Impact factor: 3.872

8.  Characterization of Direct Perturbations on Voltage-Gated Sodium Current by Esaxerenone, a Nonsteroidal Mineralocorticoid Receptor Blocker.

Authors:  Wei-Ting Chang; Sheng-Nan Wu
Journal:  Biomedicines       Date:  2021-05-13

Review 9.  Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease.

Authors:  Nina Vodošek Hojs; Sebastjan Bevc; Robert Ekart; Nejc Piko; Tadej Petreski; Radovan Hojs
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-11

10.  Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.

Authors:  Rajiv Agarwal; Peter Kolkhof; George Bakris; Johann Bauersachs; Hermann Haller; Takashi Wada; Faiez Zannad
Journal:  Eur Heart J       Date:  2021-01-07       Impact factor: 29.983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.